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In most neurodegenerative disorders,
including multiple sclerosis, Parkinson’s
disease, and Alzheimer’s disease, a
massive neuronal cell death occurs as a
consequence of an uncontrolled
inflammatory response, where activated
astrocytes and microglia and their
cytotoxic agents play a crucial
pathological role. Current treatments
for these diseases are not effective. In
the present study we investigate the
effect of thiadiazolidinones derivatives,
which have been recently suggested that
could play a role in neurodegenerative
disorders. We have found that
thiadiazol idinones  are  potent
n e u r o p r o t e c t o r  c o m p o u n d s .
T h i a d i a z o l i d i n o n e s  i n h i b i t e d
inflammatory activation of cultured
brain astrocytes and microglia by
diminishing lipopolysaccharide-induced
interleukin 6, tumor necrosis factor a,
inducible nitric oxide synthase, and
inducible cyclooxygenase type 2
e x p r e s s i o n .  I n  a d d i t i o n ,
thiadiazolidinones inhibited tumor
necrosis factor a  and nitric oxide
production and, concomitantly,
protected cortical neurons from cell
death induced by cell-free supernatant
from activated microglia. The
n e u r o p r o t e c t i v e  e f f e c t s  o f
thiadiazolidinones are completely
inhibited by the peroxisome
proliferator-activated receptor gamma
antagonist GW9662. In contrast the
GSK-3b inhibitor LiCl did not show any
effect.  These findings suggest that
thiadiazolidinones potently attenuate
lipopolysaccharide-induced neuro-
inflammation and reduces neuronal
death by a mechanism dependent of
peroxisome proliferator-activated
receptor gamma activation.
Inflammatory activation of neuronal, as
well as glial cells is believed to contribute
to cell death and damage during
neurological disease. One of the hallmarks
of neurodegenerative and inflammatory
pathologies is the increased number of
activated astrocytes and microglia in
response to the pathological stimulus (1,2).
Under normal conditions, brain microglia,
the functional equivalent of macrophages
in the central nervous system (3), are
involved in immune surveillance and host
defense against infectious agents (4).
However, in response to brain injury,
infection, or inflammation, microglia
readily become activated in a way similar
to peripheral tissue macrophages. Now,
there is a growing evidence that toxic
mediators, including tumor necrosis factor
(TNF)-a , interleukin (IL)-6, and nitric
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oxide (NO), produced by activated
microglial cells might be involved in the
pathogenesis of various neurodegenerative
diseases such as Parkinson’s disease,
Alzheimer’s disease, multiple sclerosis,
and the AIDS dementia (3,5,6).
Astrocytes, which are responsible for
maintaining the homeostasis of the brain
tissue, also participate to a large extend in
the neuroimmune responses (7,8). Hence,
it is of great interest to find a means to
modulate microglial activation in central
nervous system inflammatory responses
for the therapeutic intervention against
these neurodegenerative diseases.
Thiadiazolidinones (TDZDs) are small
heterocyclic thiadiazolidinones, which
were synthesized following a pathway
which is based on the reactivity of N -
alkyl-S-(N’-(chlorocarbonyl)amino)
isothiocarbamoyl chlorides with
isocyanates (9). They are small molecules
with favourable ADME-Tox drugable
properties, such as oral bioavailability and
blood-brain barrier penetration (10) and
they have been shown to be non-ATP
competitive glycogen synthase 3b (GSK-
3b) inhibitors  (11). TDZDs have been
postulated that could be of potential
therapeutic use for the treatment of
Alzheimer´s disease and other important
unmet pathologies as diabetes type II,
cancer and chronic inflammatory
processes (12,13). Preliminary in vitro
studies suggest potential neuroprotective
effects of TDZDs against several insults,
s u c h  a s  6 - O H D P A  ( 1 4 ) ,
lipopolysaccharide (LPS) and glutamate
(15).
The somehow chemical structure-related
derivatives to TDZDs, and recently FDA
approved thiazolidinediones (TZDs), such
as rosiglitazone, pioglitazone, and
troglitazone, are known agonists of the
peroxisome proliferator-activated receptor
gamma (PPARg) (16,17). PPARs are
members of the nuclear hormone receptor
superfamily of  l igand-act ivated
transcription factors, which includes
retinoid, steroid, and thyroid hormone
receptors, that regulate transcription of
distinct genes through heterodimerization
with the retinoid X receptors (RXR) (18).
The PPARg receptor subtype seems to
play a pivotal role in the regulation of
cellular proliferation, differentiation, and
inflammation. It has been recently shown
that PPARg ligands, including TZDs, have
potent anti-inflammatory effects, such as
the suppression of TNF-a  and IL-1b,
inducible nitric oxide synthase (iNOS),
and cyclooxygenase type 2 (COX-2) (19-
25). Of relevance to CNS disease is that
PPARg agonists have been demonstrated
to have similar anti-inflammatory effects
on astrocytes and microglial cells (review
in (26)).
Here we demonstrate a potent anti-
inflammatory effect of two TDZD
compounds, NP00111 and NP01138 (Fig.
1), in primary cultures of cortical neurons,
astrocytes, and microglia. Our results
indicate that both compounds act broadly
to inhibi t  the  product ion of
proinflammatory and neurotoxic products
elaborated by LPS-stimulated astrocytes
and microglial cells. Concomitantly,
TDZDs also exert a neuroprotective effect
in primary cultures of cortical neurons
treated with cell-free supernatant from
LPS-stimulated microglia. Our results
suggest that the effects of TDZDs are
dependent on PPARg activation, as the
PPARg antagonist GW9662 abolished
them. The capacity of TDZDs to suppress
the expression of inflammatory cytokines
and their protective action on neurons
suggests that these agents may be of value
in the treatment of Alzheimer disease or
other inflammatory diseases.
EXPERIMENTAL PROCEDURES
Primary cell cultures.
Primary cortical neuronal cultures were
prepared from the cerebral cortex of E18
rats, according to published protocols (27).
After removal of the meninges, the
cerebral cortex was dissected and
dissociated in DMEM medium (Life
Technologies) containing 10% fetal
bovine serum (FBS, Gibco, Eggenstein,
Germany). After washing, cells were
plated on poly-lysine (20 mg/ml; Sigma)
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and gelatin (250 mg/ml; Sigma)-coated
plates or cover-slips and the cultures were
maintained in Neurobasal medium with B-
27 supplements. In these conditions, the
purity of the neuronal population was
> 9 8 % ,  a s  d e t e r m i n e d  b y
immunofluorescence analysis using anti-b-
tubulin and anti-microtubule-associated
protein 2 antibodies.  All experiments
were carried out with 7-day-old cultures.
Astrocytes were prepared from neonatal
(P2) rat cerebral cortex. Briefly, after
removal of the meninges the cerebral
cortex was dissected, dissociated, and
incubated with 0.25% trypsin/EDTA at
37ºC for 1 hour. After centrifugation, the
pellet was washed 3 times with HBSS
(Gibco) and the cells were plated on non-
coated flasks and maintained in
HAMS/DMEM (1:1) medium containing
10% FBS. After 15 days the flasks were
agitated on an orbital shaker for 12 hours
at 250 rpm at 37ºC, and the non-adherent
oligodendrocytes and microglial cells were
removed. After 7 days the flasks were
agitated again to remove any remaining
microglia cells and then trypsinized and
expanded at a 1:5 ratio in complete
medium. In these conditions, the purity of
the astrocytes population was >95%, as
determined by immunofluorescence
analysis using anti-OX-42 to detect
microglial cells, anti-CNPase to detect
oligodendrocyte contamination, and anti-
glial fibrillary acidic protein (GFAP) to
identify astrocytes.
Primary microglial cells were prepared
from 15-day-old mixed glial cultures, as
described above. Briefly, 15-day-old
mixed glial cultures were agitated on an
orbital shaker for 12 hours at 250 rpm at
37ºC. The supernatant was collected,
centrifuged at 1500xg for 10 minutes, and
the cellular pellet containing the microglial
cells resuspended in HAMS/DMEM (1:1)
containing 10% FBS and seeded at a
density of 2-4x105 cells/cm2 on uncoated
plates. Cells were allowed to adhere for 2
hours and the medium was removed to
eliminate non-adherent oligodendrocytes
and new fresh medium containing 10
ng/ml of GM-CSF was added. The purity
of microglia obtained by this procedure
was >98% as determined by
immunofluorescence with the OX42
antibody.
Treatment of glial and neuronal cultures.
TDZDs (50 mM) were added to the culture
medium 1 hour before exposure to LPS
(10 mg/ml), and cells were incubated for
24 hours before tissue culture medium was
collected, and the cells were evaluated for
cytokine, iNOS, or COX-2 expression. In
the case of neuronal cultures, conditioned
medium from control and LPS-treated
microglia was subsequently transferred to
cortical neuron cell cultures, which were
then incubated for an additional 24 hours
before cells were collected and assayed for
neuronal apoptotic cell death and
expression of cytokines.
Antibodies. Mouse monoclonal antibodies
to b-tubulin, MAP2, and GFAP were from
Sigma (St. Louis, MI). Mouse anti-OX-42
monoclonal antibody was purchased from
Serotec  (Duseldorf ,  Germany) .
Monoclonal anti-CNPase was from
Sternberger (Baltimore, MD), and
polyclonal anti-IL-6, anti-TNF-a , anti-
COX-2, and anti-iNOS antibodies were
from Santa Cruz (Santa Cruz
Biotechnologies, CA).
Immunocytochemistry . Neurons were
stained with an antibody against b-tubulin,
a marker for microtubules. Microglia were
visualized by staining for the CR3
complement receptor with monoclonal
antibody OX-42 and astrocytes were
stained with an antibody against GFAP, an
intermediate filament protein whose
synthesis is restricted to astrocytes. At the
end of the treatment period the cultures,
grown on glass cover-slips in 24-well cell
culture plates, were washed with
phosphate-buffered-saline and fixed for 30
minutes with 4% paraformaldehyde at
25°C, and permeabilized with 0.1% Triton
X-100 for 30 minutes at 37ºC. After 1
hour incubation with the corresponding
primary antibody, cells were washed with
phosphate-buffered-saline and incubated
with an Alexa-labeled secondary antibody
(Molecular Probes; Leiden, The
Netherlands) for 45 minutes at 37°C.
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Subcellular localization was determined
using a TCS SP2 laser scanning spectral
c o n f o c a l  m i c r o s c o p e  ( L e i c a
Microsystems). The images were obtained
using a series of 0.5 mm (depth) spaced
cell fluorescent slices (Z axis).
Quantitative analysis of labeled cells was
undertaken using the image analySIS
software (Soft Imaging System Corp.
Münster, Germany). Areas to be counted
were traced at low power and at least three
different counting fields were selected at
random.
Measurement of apoptosis. To calculate
the extend of apoptotic cell death, cortical
neuronal cultures were treated or not with
NP00111 or NP01138, incubated with
glutamate (100 mM), staurosporine (50
nM), or cell-free supernatant from LPS-
s t i m u l a t e d  m i c r o g l i a ,  a n d
phosphatydilserine (PS) exposure on the
surface of apoptotic cells was detected by
confocal microscopy after staining with
Annexin V-FITC (Bender MedSystems,
Vienna, Austria).
T N F - a  assay. TNF-a  secreted in
astrocytes and microglial cultures was
measured by specific ELISA using rat
monoclonal anti-rat TNF-a  antibody as
capture antibody and horseradish
peroxidase polyclonal anti-rat TNF-a  as
detection antibody (R&D Systems).
Nitrite determinations. The production of
NO was monitored by measuring the
content of nitrite, one of the end products
of NO oxidation, by a procedure based on
the diazotidation of nitrite by sulfanilic
acid (Griess reaction). Twenty-four hours
after incubation of astrocytes and
microglia cells with LPS or neuronal
cultures with conditioned medium from
LPS-treated microglia, in the absence or
presence of TDZDs, fifty microliters of
sample aliquots were mixed with 50 ml of
Griess reagent in 96-well plates and
incubated at 25ºC for 10 minutes. The
absorbance at 550 nm was measured on a
microplate reader.
T r a n s i e n t  t r a n s f e c t i o n s . Murine
hippocampal neuronal cell line HT22 was
propagated and maintained in DMEM
medium containing 10% FBS, 40 mg/ml
gentamicine and 2 mM glutamine at 37ºC
and 5% CO2. Semiconfluent cultures were
transfected with the reporter plasmid
pPPRE-tk-luc, containing three PPARg
consensus binding sites upstream of a
minimal promoter, together with PPARg
and RXRa  expression vectors, using
Transfast (Promega Corporation, Madison,
WI, USA) according to the manufacturer’s
guidelines. Typically, cells received 0.2 mg
of luciferase reporter plasmid, 0.2 mg of
PPARg, and 50 ng of RXRa , and were
harvested 24 hours after treatment with
rosiglitazone (30 mM), NP00111 (50 mM),
NP01138 (50 mM) and/or 9-cis retinoic
acid (9-cis RA, 1 mM), for determination
of luciferase and b-galactosidase (to
determine transfection efficiency)
activities. Each transient transfection
experiment was repeated at least three
times in triplicate.
Statistical determinations. The data shown
are the means±s.d. of at least three
independent experiments. Statistical
comparisons for significance between cells
with different treatments were performed
using the Student’s test, with p ≤0.05.
RESULTS
NP00111 and NP01138 inhibit
inflammatory activation of cultured glial
cells.
Potential anti-inflammatory activity of
TDZDs was first tested by evaluating the
production of inflammatory mediators
from cultured astrocytes and microglial
cells. First, we performed a dose-response
curve of nitrite production (an indirect
quantification of NO generation) by
astrocytes and microglia cells. Astrocytes
and microglia were incubated with
different concentrations of TDZDs for 1
hour and then cells were cultured for
another 24 hours with LPS. As shown in
Fig 2, NP00111 and NP01138 dose-
dependtly inhibited the production of
nitrite (Fig 2A) and the expression of
COX-2 (Fig 2B) induced by LPS
stimulation. The effects of TDZDs were
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not caused by a loss of cell viability, as the
24 hour exposure of astrocytes and
microglial cells to NP00111 or NP01138
did not significantly alter cell viability
(data not shown). The suppressive effects
of both TDZDs were stronger at higher
concentrations (50 mM) and, therefore we
used this concentration henceforth.
We then analyzed more thoroughly the
effects of TDZDs on LPS-stimulated
primary cultures of astrocytes. When
primary astrocytes were stimulated with
LPS we observed once more a significant
induction of nitrite production and also of
TNF-a levels in the culture medium (2.0-
and 4.0-fold, respectively), which was
totally inhibited by NP00111 and
NP01138 treatment (Fig. 3A). To further
study the inhibitory effect of NP00111 and
NP01138 on astrocytes activation, we next
examined whether these compounds
affected the LPS-induced intracellular
accumulation of TNF-a and IL-6 (another
pro-inflammatory cytokine). In addition,
we also studied the accumulation of
inducible COX-2 and iNOS. The enzyme
iNOS is responsible for the generation of
NO (28), and overexpression of COX-2 in
activated microglia and astrocytes appears
central to many neuroinflammatory
conditions. We studied this by
immunofluorescence analysis followed by
confocal microscopy. As shown in Fig.
3B-C the protein levels of TNF-a and IL-6
were clearly increased after LPS treatment
of astrocytes and treatment of the cultures
with NP00111 or NP01138 completely
abrogated this effect. In addition, in basal
conditions, COX-2 and iNOS protein
levels were barely detectable in astrocytes
cultures, and their content was
significantly induced after LPS treatment.
Addition of NP00111 and NP01138
drastically inhibited LPS-induced COX-2
and iNOS expression. A similar cellular
density is present in all microphotographs,
as assessed by DAPI staining (data not
shown).
Similar results were obtained with LPS-
activated microglia. Microglia cultures
treated with LPS showed an increase in the
secreted levels of nitrite and TNF-a (3.0-
and 4.2-fold respectively, compared with
basal levels) (Fig 4A) and, again, a
complete inhibition in nitrite and TNF-a
levels was observed in microglia cultures
treated with either NP00111 or NP01138.
Also, addition of TDZD compounds to the
culture medium of microglial cells
strongly inhibited the LPS-induced
expression of the two citokines, IL-6 and
TNF-a , as well of COX-2 and iNOS
intracellular levels (Fig 4B-C). A similar
cellular density is present in all
microphotographs, as assessed by DAPI
staining (data not shown).
Altogether these results suggest that
NP00111 and NP01138 inhibit
inflammatory activation of cultured glial
cells.
NP00111 and NP01138 protect from
inflammation-induced neurodegeneration.
We next investigated the effect of
NP00111 and NP01138 on neuronal cell
death induced by cell-free supernatant
from LPS-stimulated microglia (SP). Rat
embryonic cortical neurons were
stimulated with supernatant from LPS-
activated microglia in the presence or
absence of TDZD compounds. Treatment
of cultures with cell-free supernatants
from LPS-stimulated microglia resulted in
a significant induction in the number of
Annexin V-positive cells, compared with
the control cultures (Fig. 5). The addition
of NP00111 or NP01138 to neuronal
cultures treated with conditioned medium
from LPS-activated microglia cells
suppressed neuronal cell death, suggesting
that TDZDs could mediate their
neuroprotective effects by blocking the
effects of activated microglial-derived
cytotoxic factors.
Neurodegenera t ion  induced  by
conditioned medium from LPS-activated
microglia was associated with an increase
in neuronal expression of TNF-a, IL-6,
iNOS, and COX-2 (Fig. 6A-B), in a
manner similar to the one observed in glial
cells treated with LPS. In addition, as
observed in astrocytes and microglia, the
TDZD compounds NP00111 and
NP01138 completely blocked the
induction of these genes in neuronal
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cultures. A similar cellular density is
present in all microphotographs, as
assessed by DAPI staining (data not
shown). In line with these results, and as
shown for glial cells, the release of nitrite
to the culture medium was significantly
increase after incubation of the neurons
with supernatant from LPS-activated
microglia (1.9-fold compared with basal
values), and this increase was completely
abolished in cultures treated with both
TDZDs (Fig. 6C).
NP00111 and NP01138 protect neurons
from apoptotic and excitotoxic stress.
We next analyzed if the neurodegeneration
induced by other insults could also be
prevented by TDZD compounds. To this
end, we treated cortical neurons with 50
nM staurosporine (apoptotic stimulus) or
100 mM glutamate (excitotoxic insult) and
determined apoptosis by Annexin V
staining. As shown in Fig. 7, both stimuli
elicited an induction in the number of
apoptotic cells, similar to those found
when inflammatory stimulus was used.
Addition of NP00111 or NP01138
protected neuronal cultures from both
staurosporine-induced apoptosis and
glutamate-induced excitoxicity. These
observations indicate that the protective
role of the TDZDs is not restricted to a
specific insult.
Dependence of TDZDs effects on PPARg
activation.
The structural similarities between
NP00111 and NP01138 and the
antidiabetic TZDs, such as rosiglitazone
(Figure 1) prompted us to analyze a
possible involvement of the nuclear
receptor PPARg in the actions of these
compounds. TZDs are known ligands of
PPARg (16), whose activation has been
shown to play a key role in cellular
proliferation, differentiation, and
inflammation (29,30). This fact suggests
the possibility that PPARg activation could
be involved in the mediation of the effects
of these TDZDs in neural cells. We first
tested this hypothesis in transient
transfection experiments by using a
reporter construct containing three
consensus PPARg  response elements
(pPPRE-tk-luc). As a positive control we
used rosiglitazone, a well-known high
affinity ligand of PPARg. In HT22 cells
transfected with pPPRE-tk-luc and
expression vectors for PPARg and its
partner RXRa, a significant stimulation of
luciferase activity was observed after
treatment with NP00111 and NP01138
(Fig. 8). This increase was similar or even
higher (in the case of NP01138) to the one
observed for rosiglitazone. These results
demonstrate that these compounds are able
to activate a reporter construct containing
PPARg consensus response elements. It
has been shown that the PPARg receptor
activates transcription acting as a
permissive PPARg /RXR heterodimer
(review in (31)). This kind of nuclear
receptor heterodimers can be activated by
ligands of either RXR or its partner
receptor and are synergistically activated
in the presence of both ligands. Therefore,
we next analyzed the response of the
PPRE construct to the RXR ligand 9-cis
retinoic acid (9-cis -RA) alone or in
combination with rosiglitazone, NP00111
or NP01138. Fig. 8 shows that treatment
of HT22 cells with 9-cis-RA resulted in a
significant increase (1.5-fold) in promoter
activity. Moreover, when the cells were
incubated with 9-cis-RA together with
rosiglitazone, NP00111 or NP01138, a
larger activation of the PPRE reporter
construct was observed. These data further
suggest that the effects of the TDZDs
could be mediated by activation of
PPARg.
In view of the data shown above, we next
analyzed whether activation of PPARg is
involved in the neuroprotective and anti-
inflammatory effects of the TDZDs. Since
TDZDs have also been described as GSK-
3 inhibitors and it has been postulated that
could be of potential therapeutic use for
the treatment of Alzheimer´s disease, we
also tested the effect of LiCl, an inhibitor
of GSK-3b, on neuronal cell death induced
by conditioned media form activated
microglia and pro-inflammatory activity.
To this end, neuronal cultures were
pretreated with the selective PPARg
antagonist, GW9662 (32-34) before
exposure to NP00111 and NP01138 and
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cell-free supernatant from LPS-activated
microglia. Other neuronal cultures were
pretreated with LiCl prior to stimulation
with the conditioned media. As shown in
Fig. 9A and 9B, GW9662 suppressed both,
the blocking effect of TDZDs on COX-2
induction and their neuroprotective effects
in cultures of cortical neurons. Treatment
of neuronal cultures with the GSK-3
inhibitor LiCl (Fig 9B and 9C) did not
have any effect upon the increase in
annexin V-positive cells elicited by
treatment with conditioned media from
microglia. The induction in COX-2 levels
was also not altered by incubation of
neuronal cultures with LiCl. These results
suggest an involvement of the nuclear
receptor PPARg in the neuroprotective
action of both compounds.
Finally, we analyzed whether the action of
NP00111 and NP01138 on glial cells was
also dependent on PPARg  activation.
Astrocytes and microglia cultures were
then treated with GW9662 or LiCl and
nitrite production was measured after LPS
stimulation. As can be seen in Figure 10,
the nitrite levels in the culture medium of
astrocytes and microglia stimulated with
LPS were very similar to those found in
control cultures. On the other hand,
incubation of these cultures with the
PPARg antagonist GW9662 significantly
blocked the inhibitory effect of both
TDZDs on nitrite production after LPS
stimulation. These data strongly suggest
that NP00111 and NP01138 are acting
through activation of the PPARg receptor
and not through their inhibition of GSK-
3b activity.
DISCUSSION
In the present work, we have demonstrated
that NP00111 and NP01138, two
thiadiazolidinone compounds, suppress
inflammatory activation of astrocytes and
microglia in vitro and protect cortical
neurons from cell death, and that these
effects could be mediated by a mechanism
apparently dependent on PPARg
activation.
Inflammation plays a central role in the
pathogenesis of several brain disorders and
neural injury (35) and develops as a
consequence of activation of astrocytes
and microglial cells (36). Inflammatory
cells generate potentially damaging nitric
oxide, oxygen free radicals, proteases,
arachidonic acid derivatives, and
cytokines, which could be mediators of the
so-called secondary damage (35).
Augmented activation of microglia and
increased levels of inflammatory
compounds have been localized at the sites
of neurodegeneration in several disorders
like Alzheimer’s disease, multiple
sclerosis, AIDS-associated dementia, and
post-traumatic lesions. Stimulated
astrocytes are also an important cellular
source of inflammatory mediators in the
CNS and the proliferation of astrocytes is
frequently observed after brain injury (37).
Here we show that NP00111 and NP01138
are strongly anti-inflammatory against
LPS-induced responses in rat primary
astrocytes and microglia. Our results
demonstrate that NP00111 and NP01138
inhibit NO production and TNF-a release
from LPS-activated astrocyte and
microglia cultures. In addition, these
TDZDs completely blocked intracellular
accumulation of cytokines, such as IL-6
and TNF-a, and the expression of iNOS
and the pro-inflammatory gene COX-2, in
response to LPS.  Hence, these results
suggest that these compounds could be of
therapeutical value in those brain diseases
and brain damage where inflammation
processes are involved.
 We have also shown that NP00111 and
NP01138, not only prevent the
inflammatory response by glial cells, but
also have a neuroprotective activity in
primary cortical neurons. These
compounds protect cortical neurons from
apoptosis induced by cell-free medium
from LPS-activated microglial cultures. In
addition, TDZDs protected cortical
neurons against staurosporine-induced
apoptosis and glutamate-induced
excitotoxicity, suggesting that these
compounds are potent neuroprotective
agents against a wide variety of neuronal
insults. Neuroprotection by TDZDs was
coincident with a decrease in cytokine,
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COX-2, and iNOS expression, and NO
production. Accumulating data indicates
that, in addition to glial cells, neurons can
express iNOS (38-40), whose production
of NO can be neurotoxic (41,42).
Although a role for COX-2 in healthy cells
is not clear, under pathological conditions,
the induction of COX-2 in neurons has
been well demonstrated, and this induction
correlates with apoptosis. COX-2 is
rapidly induced in hippocampal and
cort ical  neurons fol lowing an
electroconvulsive seizure (43). COX-2 is
also induced in models of cerebral
ischemia and there is a direct correlation
between the extent of COX-2 mRNA
induction and the severity of subsequent
tissue damage (44).
TDZDs were first described as GSK-3b
inhibitors and were postulated that could
be of potential therapeutic use for the
treatment of Alzheimer´s disease (AD) and
other important unmet pathologies as
diabetes type II, cancer and chronic
inflammatory processes (12). So far, in
vivo studies have been only performed
using the tet/GSK-3 transgenic model (45)
confirming the potential role of TDZDs as
therapeutic drugs for AD. However, the
results presented here indicate that the
effects of two TDZDs, the NP00111 and
NP01138 compounds, on neuroprotection
and inhibition of glial activation by LPS
stimulation are mediated by activation of
the PPARg nuclear receptor. In fact, we
show that NP00111 and NP01138 can
activate a reporter construct containing
consensus PPARg binding sites and that
this activation is further enhanced by 9-
cis-RA, a behavior characteristic of a
classical  PPARg /RXR permissive
h e t e r o d i m e r .  M o r e o v e r ,  t h e
neuroprotective effects of these TDZDs
are suppressed by GW9662, a specific
antagonist of PPARg. Altogether, these
results suggest that the neuroprotective
and anti-inflammatory effects of NP00111
and NP01138 could be mediated through
PPARg activation. In line with these
observations, there are a number of reports
showing inhibitory effects of different
PPARg ligands on the production of
microglia-derived pro-inflammatory
factors (review in (26)). Petrova et al (46)
were the first to report that 15-deoxy-∆-
12,14-prostaglandin J2 (15dPG-J2), a
potent ligand of PPARg, strongly inhibited
LPS-induced iNOS and subsequent NO
production in the mouse microglial cell
line BV-2. Subsequent studies by
Bernardo et al (22) demonstrated that
15dPG-J2 and ciclitazone attenuated TNF-
a and NO production in primary cultures
of microglia stimulated with LPS. It has
been also revealed that a variety of PPARg
agonists, including the nonsteroideal anti-
i n f l a m m a t o r y  d r u g s  (NSAIDs)
indomethacin and ibuprofen, the
thiazolidinediones troglitazone and
ciclitazone, and 15dPG-J2, inhibited b-
amyloid stimulation of neurotoxic
molecules by microglia. However, and in
contrast with the results presented here,
direct application of these agonists to
cortical neurons did not significantly
improved neuron survival, indicating that
the agonists indirectly protect neurons
through effects on microglia (47).
Conversely, and in agreement with our
results, a direct neuroprotective effect of
NSAIDs and 15dPG-J2 has also been
shown in cerebellar granule neurons (48).
Lastly, there is in vivo evidence
suggesting that 15dPG-J2 and pioglitazone
can reduce the severity of experimental
autoimmune encephalomyelitis (49,50).
Our results extend these studies and
present new potential ligands of PPARg as
robust agents against neural injury.
Collectively, our results indicate that
TDZDs can be very effective
neuroprotective and anti-inflammatory
compounds in neuronal cells through, at
least in part, activation of the nuclear
receptor PPARg . Our study suggests
possible therapeutic uses of TDZDs in
certain brain disorders, such as multiple
sclerosis, Parkinson’s, and Alzheimer’s
diseases, where inflammatory responses
p l a y  a  m a j o r  r o l e .
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Figure 1. Structure of the thiadiazolidinones compounds NP00111 and NP01138 and the
thiazolidinedione rosiglitazone.
Figure 2. Dose response curve of TDZD compounds. A, Either rat primary astrocytes or
microglia cultures were treated for 24 h with LPS (10 mg/ml) in the absence or presence of
different concentrations of TDZDs, and the production of nitrite was evaluated by the Griess
reaction. Cells were pretreated with TDZDs for 1 hour before LPS stimulation. Values
represent the means±s.d. from three different experiments. *,p≤ 0.05; **,p≤ 0.01; ***,p≤
0.001, versus LPS-treated cells. B, Rat primary astrocyte cultures were treated with LPS (10
mg/ml) in the absence or presence of different concentrations of TDZDs, and COX-2 was
evaluated by immunofluorescence analysis and confocal microscopy using specific
antibodies, as described in Experimental Procedures. Bar scale, 20 mm. Representative results
of three different experiments are shown.
Figure 3. TDZDs inhibited inflammatory activation of astrocyte cultures. A, Rat primary
astrocyte cultures were treated for 24 hours with LPS (10 mg/ml) in the absence or presence of
TDZDs (50 mM) and the production of nitrite and TNF-a  was evaluated by the Griess
reaction or specific ELISA. Values represent the means±s.d. from three different experiments.
***,p≤ 0.001, versus LPS-treated cells. B, Rat primary astrocyte cultures were treated as in A
and the expression of TNF-a, IL-6, COX-2, and iNOS was evaluated by immunofluorescence
analysis and confocal microscopy using specific antibodies, as described in Experimental
Procedures. Bar scale, 20 mm. Representative results of three different experiments are
shown. C, Quantitative confocal analysis. The percentage of stained cells was analyzed using
the analiSIS software, as described in Experimental Procedures.
Figure 4. TDZDs inhibited inflammatory activation of microglial cultures. A, Rat primary
microglial cultures were treated for 24 hours with LPS (10 mg/ml) in the absence or presence
of TDZDs (50 mM) and the production of nitrite and TNF-a was evaluated by the Griess
reaction or specific ELISA. Values represent the means±s.d. from three different experiments.
***,p≤ 0.001, versus LPS-treated cells. B, Rat primary microglial cultures were treated as in
A  and the expression of TNF-a , IL-6, COX-2, and iNOS was evaluated by
immunofluorescence analysis and confocal microscopy using specific antibodies, as described
in Experimental Procedures. Bar scale, 20 mm. Representative results of three different
experiments are shown. C, Quantitative confocal analysis. The percentage of stained cells was
analyzed using the analiSIS software, as described in Experimental Procedures.
Figure 5. TDZDs protected cultured cortical neurons from activated microglia citotoxicity.
Rat primary neuronal cultures were treated for 24 hours with microglia-activated supernatant
(SP) in the absence or presence of NP00111 and NP01138, and apoptosis was assessed by
Annexin V-FITC staining. Nuclear 4,6-diamino-2-phenylindole (DAPI) staining is indicated
(blue). Bar scale, 20 mm. A, Representative confocal images of three different experiments are
shown. B, Quantitative confocal analysis. The percentage of stained cells was analyzed using
the analiSIS software, as described in Experimental Procedures.
Figure 6. TDZDs inhibited expression of inflammatory mediators in cultured neurons. A, Rat
primary neuronal cultures were treated for 24 hours with cell-free supernatant from LPS-
stimulated microglia (SP) in the absence or presence of NP00111 or NP01138, and expression
of TNF-a, IL-6, COX-2, and iNOS was evaluated by immunofluorescence analysis and
confocal microscopy using specific antibodies, as described in Experimental Procedures. Bar
scale, 20 mm. Representative results of three different experiments are shown. B, Quantitative
confocal analysis. The percentage of stained cells was analyzed using the analiSIS software,
as described in Experimental Procedures. C, Rat primary neuronal cultures were treated as in
Thiadiazolidinones prevent neuroinflammation
12
A and the production of nitrite was evaluated by the Griess reaction. Values represent the
means±s.d. from three different experiments. ***,p≤ 0.001, versus LPS-treated cells.
Figure 7. TDZDs protected cultured neurons from citotoxicity induced by staurosporine and
glutamate. Rat primary neuronal cultures were treated for 24 hours with either 50 nM
staurosporine A or 100 mM glutamate B in the absence or presence of NP00111 or NP01138,
and apoptosis was assessed by Annexin V-FITC staining. Nuclear 4,6-diamino-2-
phenylindole (DAPI) staining is indicated (blue).  Bar scale, 20 mm. Representative results of
three different experiments are shown. The percentage of stained cells was analyzed using the
analiSIS software, as described in Experimental Procedures.
Figure 8. Activation of a PPRE reporter gene by TDZDs and rosiglitazone alone or in the
presence of 9-cis retinoic acid. HT22 cells were transfected with 0.2 mg of the pPPRE-tk-luc
reporter plasmid and expression constructs for PPARg (0.2 mg) and RXR (50 ng). Cells were
harvested 24 hours after treatment with rosiglitazone (30 mM), NP00111 (50 mM), NP01138
(50 mM) and/or 9-cis retinoic acid (9-cis RA, 1 mM) and luciferase activity of cell lysates was
determined. Data are expressed relative to the basal values and represent the mean±s.d.
luciferase activity determined in triplicate in three independent experiments. *p≤ 0.05; **p  ≤
0.01; ***p ≤ 0.001, versus control non-treated cultures.
Figure 9. Effect of GW9662 and the GSK-3b inhibitor LiCl on neuronal viability. Rat
primary neuronal cultures were treated for 24 hours with microglia-activated supernatant (SP)
in the absence or presence of NP00111 or NP01138 and expression of COX-2 and apoptosis
were analyzed as described in Experimental Procedures. Some cultures were pre-incubated 1
hour with 30 mM GW9662 prior to the addition of the TDZDs A, or with 20 mM LiCl prior to
the addition of conditioned media form LPS-activated microglia B. Bar scale, 20 mm .
Representative results of three different experiments are shown. C, Quantitative confocal
analysis. The percentage of stained cells was analyzed using the analiSIS software, as
described in Experimental Procedures.
Figure 10. Effect of GW9662 and the GSK-3b inhibitor LiCl on nitrite production by glial
cells. Either rat primary astrocytes or microglia cultures were treated for 24 hours with LPS
(10 mg/ml) in the absence or presence of NP00111 or NP01138, and the production of nitrite
was evaluated by the Griess reaction. Some cultures were pre-incubated 1 hour with 30 mM
GW9662 prior to the addition of TDZDs or with 20 mM LiCl, prior to stimulation with LPS.
Values represent the means±s.d. from three different experiments. ***,p≤ 0.001 versus LPS-
treated cells.
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